Groupe Athena Inc (OTC:GATA)

Third Quarter Fiscal 2014

• The company reported revenue of $14,471,625, an increase of $1,093,173 over the same period in 2013.
• The company reported EPS of $0.03 compared to $0.03 for the same quarter 2013.

The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these exporter companies are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

The company also continues to negotiate with several Indian drug companies for the manufacture of generic pharmaceuticals that the company intends to market in the United Kingdom under the anticipated license they are in the process of applying for.

MUMBAI, INDIA--(Marketwired - Mar 11, 2014) - Groupe Athena, Inc. (OTC Pink: GATA) made the following announcement:

The guidance contained below represents forecasts, which indicate possible outcomes and are provided to assist investors with the development of earnings estimates. While Groupe Athena, Inc. believes that these forecasts represent the best estimate of management as to future events, actual events may differ from these forecasts, and such differences could be material. These forecasts are subject to risks identified under "Safe Harbor Statement" below.

Groupe Athena, Inc. announced today they have approximately $60 million in customer orders that they are currently processing, and they are hopeful that this number will increase in the near term. Based on the orders in hand the company expects to be able to convert at least one half or approximately $30 million into revenue during the current fiscal year ending June 30, 2014. This would put total current year revenue projections at $65,000,000, in line with projections and provide a solid revenue base to build on for the 2015 fiscal period.

As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. The Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

MUMBAI, INDIA--(Marketwired - Mar 10, 2014) -  Groupe Athena, Inc. (OTC Pink: GATA) today posted their quarterly results for the three months ending December 31, 2013. The company reported revenues of $17,961,452 which is an increase of 21% when compared to the corresponding period in 2012 and represents the strongest 6 month earnings period in the company's history. Operating income for the quarter was also strong at $3, 097,791, an increase of over 26% from $2.45 million for the same period in 2012.

Net income after taxes and depreciation for the period was $2,083,606 or $.044 per share.

With regard the continued strong growth, the company's President, Ms. D Purohit, stated, "I can't put into words how exciting it is to see our dreams become reality. Our core business is thriving and our expansion plans are proceeding as expected. We fully expect 2014 to be a breakout year for Groupe Athena, Inc."

The company reiterates that the strong increase in operating income is due to the continued increases in gross margins and they anticipate further increases as more work is transitioned in-house. Operating margins are approaching 20% currently and management remains committed to attain 40% gross margins over the next few years.

The company's order position also remains very healthy and management expects record total revenues of at least $65 million for the current fiscal year. 

Cash and cash equivalents are at record levels for the company and continue to grow and debt remains virtually non-existent.

To review the complete quarterly report please go to www.otcmarkets.com/stock/GATA/quote and click on "Financials."

The Indian pharmaceutical industry is increasingly focusing on exports to the United States and Europe and GATA is well positioned to help them get their products approved by the respective governing bodies for sales in both regions. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

MUMBAI, INDIA--(Marketwired - Sep 23, 2013) - Groupe Athena, Inc. (OTC PINK: GATA) announced on September 23, 2013 that based on the orders in hand, the company expects to achieve total revenues of $65 million in the current fiscal. The company is on track to report revenue of $18 million for the current quarter, which would reflect a growth 17.5% over the corresponding quarter of the previous year.

As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

MUMBAI, India, Feb. 12, 2013 /PRNewswire/ -- Groupe Athena, Inc. (OTCPink: GATA) announced today record revenues of $14,810,936 for the period ending December 31, 2012, which represents a 23% increase over the same period in 2011. Net after tax income for the period was $1,549,882 or $.033 per share which was also the best for any quarter to date as profit margins continue to increase.

Revenue growth for the first half of this fiscal year is also on a record pace and has increased approximately 30% year on year. With the two recent strong quarters trailing twelve month (ttm) earnings have increased to just over $.11 per share.

Cash reserves are strong and long term debt remains virtually non-existent as the Company prepares to outfit it's recently purchased new testing facility. The company reports it is still committed to funding all capital expenditures entirely from internal cash accruals without any shareholder dilution or debt increases.

Company Chairman, D. Purohit stated, "We could not be happier with our financial position and the pharmaceutical business environment in general. Many of our regional customers are now renewing contracts going forward and our efforts to develop and expand our global footprint is progressing nicely."

As previously stated, the company plans to apply for listing on the NASDAQ Bulletin Board quotation system with the completion of the audit for this fiscal year ending June 30, 2013.

MUMBAI, India, Aug. 27, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets: GATA) has announced record revenues of $44,571,386 for the recent fiscal year ended June 30, 2012, an increase of 78% over the previous year. After tax earnings increased 116% to a record $4,417,047 or $0.094 a share.

Though the company added $4,656,442 in assets, its cash position is extremely healthy with cash and short term assets of $3,286,141 as against current liabilities of $84,090. The company is proud of the fact that all equipment and other acquisitions have been made entirely from internally generated cash and it is the commitment of management that future additions to the asset base be accomplished without any further dilution or debt increases. The Company has no plans for shareholder dilution over the next 12-18 months.

MUMBAI, India, April 11, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK) announced they have released their financial results for the third quarter which ended March 31, 2012.  Total revenue for the period was $10,378,928 which is 140% greater than the same period in 2011. Net income rose to $1,184,000 compared to $731,644.

For the nine months the company also reported record revenue of $34,558,560 compared to $17,893,325. Net income for the first three quarters of the current fiscal year has more than doubled to $3,524,218 or $.075 per fully diluted share.

The company's cash increased to more than $3.5 million including the special escrow for the anticipated new facility acquisition. They are extremely excited to have been able to maintain this healthy cash position while still adding $3.61 million worth of new equipment in the last 12 months with no shareholder dilution or assumption of debt.

The company reiterates the recent guidance update which stated annualized revenue should increase to exceed $44 million. Earnings are also expected to increase similarly.

MUMBAI, India, Feb. 28, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK) announced today it has reported revenues of $11,968,232 for the recent fiscal quarter ended December 31, 2011, which combined with the 1st quarter of this fiscal year established record 6 months revenue and earnings. Total revenues for the 6 month period were $24,179,632 which exceeded any period of the same length in the company's history and nearly equaled the total revenues for the entire 2011 fiscal year.  After tax earnings also increased for the same period to $2,529,725 or $.054 per share.

The Company's Chairman, D. Purohit stated, "India's pharmaceutical industry is experiencing unprecedented growth and Groupe Athena, Inc. is uniquely poised to capitalize.  As many critical drug patents expire for large U.S. manufacturers, it opens many doors for us here. This is an exciting time to be part of our dynamic revenue growth and we look forward to further similar increases as we continue to gain market share and increase our participation in the explosive growth of our core industry."

The Company's debt to equity ratio also remains extremely healthy at over 40 to 1 with cash and short term assets of $3,530,864 and total assets of $8,650,722 as of December 31 and only $114,232 of current liabilities and $0 long term debt on the books. The company is proud of the fact that all equipment and other acquisitions have been made entirely from internally generated cash and it is the commitment of management that future additions to the asset base be accomplished without any further dilution or debt increases. The Company has no plans for shareholder dilution over the near term.

First quarter 2012 Results

•  Record revenues of $12,211,400 for the first quarter ending September 30, 2011 
•  Pretax earnings of $1,566,906, or $.033 per share which is also a record for the same period.

 With the most recent strong quarter, trailing twelve month (ttm) earnings jumped to nearly $.10 per share. The record quarterly revenue was significant in that it equaled nearly 50% of total revenue for all of the previous fiscal year.

The Company's Chairman, D. Purohit stated, "As our markets continue to expand within India and the region, we expect to see continued strong revenue and earnings growth, and with the recently reported asset additions which allow us to perform more services in-house, our margins are also increasing significantly. We are also very pleased to have a healthy backlog to build on which currently insures our growth well into fiscal 2013."

We are not sure what to make of this company: Hype or Reality.. But the guidance makes the story worth tracking, especially as shares just attained a new 52 week high of about $0.70

MUMBAI, India, Aug. 24, 2011 /PRNewswire/ -- Groupe Athena, Inc. (Pink Sheets: GATA) announced on August 15, 2011 they have approximately $60 million in customer orders that they are currently processing, and they are expecting this number to increase in the near term. Based on the orders in hand the company expects to be able to convert at least two thirds or approximately $40 million into revenue during the current fiscal year.

The company also stated that due to the recent capital investments in equipment and facilities which has increased their ability to perform more services in-house, they will to be able to increase net profit margins on future revenues by 1.5-2%. To clarify this projection the company issued the following example:

Approximate current hourly rate for outsourcing of tests: $1,750

Approximate In-house hourly rate for same process: $3-400

Based on this scenario the company expects to reduce these costs up to 80% over current levels.

The resulting savings to net earnings would have added several hundred thousand dollars to fiscal 2011 net earnings and will have a positive impact on any future earnings.

The company is on track to report revenue of $12,000,000 for the current quarter, which would be more than the first and second quarters combined of the previous fiscal year and well in line with their expectations for the current fiscal year.

The company is still committed to funding all capital expenditures entirely from internal cash accruals without any further dilution or debt increases.

As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

MUMBAI, India, Aug. 1, 2011 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK) announced today record revenues of $25,112,636 for the recent fiscal year ended June 30, 2011, more than doubling the revenues of the prior fiscal year. After tax earnings also more than doubled for the same period to $2,106,808 or $.045 per share.

The Company's Chairman, D. Purohit stated, "Of course we are very pleased with our current revenue growth and we look forward to further similar increases as we continue to gain market share and increase our participation in the explosive growth of our core industry."

The Company also announced it has a healthy cash position with minimal debt as of June 30, 2011. This is despite the fact that they purchased new equipment worth $445,893 in the third quarter. The purchase was made entirely from internal cash accruals and it is the commitment of management that all future additions to the asset base be from internally generated cash flow only, without any further dilution or debt increases. The Company has no plans for shareholder dilution over the next 24 months.

The company's order position is also very healthy and management expects to announce other related positive financial news in the near term. This is mainly due to the fact that the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company can take on added contracts and continue to anticipate further growth.

GeoTeam Note: 2012 Guidance works out to about EPS of $0.08, fully taxed (June year end)